segunda-feira, 21 de setembro de 2026
PesquisarExplore
pt.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 5, 2026

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

View original at finance.yahoo.com
Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America Average weight loss of ~17% if all patients stayed on treatment* with Wegovy® (semaglutide) tablets 25 mg (~14% regardless of if patients stayed on treatment**) in the OASIS 4 trial1 Starting dose…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • More than 100 million Americans are living with obesity

    80% confidence

  • Wegovy pill represents a significant innovation as the first and only GLP-1 pill for weight loss

    80% confidence

  • Millions have been prescribed Wegovy (semaglutide) injection 2.4 mg for weight management since 2021

    80% confidence

  • There are people interested in addressing their weight who have been waiting for a medicine that was right for them, and for many that wait is over with Wegovy pill offering powerful efficacy in a once-daily pill

    80% confidence

  • Obesity is not just a disease of lack of willpower but has underlying biology that may impede people from losing weight and keeping it off

    80% confidence

  • Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials

    80% confidence

Data points we hold from this source

Novo Nordisk A/S · us employee count10000 employees
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Frontier AI Slowdown Call Splits Industry, Rattles Capex-Sensitive Markets
Anthropic's Dario Amodei publicly called for a coordinated global slowdown in frontier AI development, a stance Microsoft echoed with a 'humanist' AI code of conduct, but Nvidia and Meta's CEOs rejected any coordinated pause days later, exposing a widening rift between safety-focused and growth-focused AI leaders. The dispute landed amid growing financial scrutiny of AI infrastructure spending — a hyperscaler capex analysis, FTC warnings against antitrust waivers for AI firms, and an 8.6% single-day stock drop in GE Vernova tied directly to the slowdown remarks — signaling investors are newly nervous about whether the AI capex boom (including Alphabet's projected $701B revenue narrative) can be justified if the pace of development itself becomes contested.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,983
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,983 factos verificados com a fonte5,304 documentos-fonte arquivados
Consulte estes dados → isubstrate.com